Recovery Is Possible As Moderna Races Its Children Vaccine

Mar. 24, 2022 1:29 PM ETModerna, Inc. (MRNA) StockNVAX, PFE, MRNA4 Comments
Juxtaposed Ideas
13.96K Followers

Summary

  • Moderna will be seeking regulatory approval for its young children's COVID-19 vaccines, ahead of Pfizer.
  • Assuming US FDA approval, there is upside potential to its projected revenue, given millions of children unvaccinated.
  • Moderna's two-dose regimen may be more popular compared to the three doses from Pfizer.
  • Based on its latest APA, Moderna also raised its FY2022 sales guidance by 10% to $21B.
  • Its pipeline is also highly promising, as its Personalized Cancer Vaccine cured two patients with head and neck cancer.

Little girl taking a vaccine from her doctor, pediatrist

Anchiy/E+ via Getty Images

Investment Thesis

Based on CDC, Moderna's (NASDAQ:MRNA) COVID-19 vaccine has been proven to offer the most effective long-term protection against hospitalization and serious illnesses. In addition, its children's COVID-19 vaccine could potentially be approved earlier than

This article was written by

13.96K Followers
I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About MRNA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on MRNA

Related Stocks

SymbolLast Price% Chg
MRNA
--